Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer

Gil-Rendo, Aurora; Martínez‐Regueira, Fernando; Zornoza, G; García-Velloso, María José; Beorlegui, Carmen; Rodríguez-Spiteri, N.

doi:10.1002/bjs.6459

Cited by 154 publications

(144 citation statements)

References 12 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…This tendency has also been reported previously [11][12][13][14][15][16]. Kawamura et al demonstrated that FDG uptake was affected by the number of metabolically active tumor cells [17].…”

Section: Discussionsupporting

confidence: 85%

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Song

Hong

Lee

et al. 2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose To determine the prognostic implications of pretreatment F-18 FDG PET/CT in patients with invasive ductal breast cancer (IDC), we evaluated the relationship between FDG uptake of the primary tumor and known prognostic parameters of breast cancer. Prognostic significance of tumoral FDG uptake for the prediction of progression-free survival (PFS) was also assessed. Materials and Methods Fifty-five female patients with IDC who underwent pretreatment F-18 FDG PET/CT were enrolled. The maximum standardized uptake value of the primary tumor (pSUVmax) was compared with clinicopathological parameters including tumor size, grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor2 (HER2), axillary lymph node (LN) metastasis, and stage. The prognostic value of pSUVmax for PFS was assessed using the Kaplan-Meier method.

show abstract

“…This tendency has also been reported previously [11][12][13][14][15][16]. Kawamura et al demonstrated that FDG uptake was affected by the number of metabolically active tumor cells [17].…”

Section: Discussionsupporting

confidence: 85%

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Song

Hong

Lee

et al. 2011

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Clinical studies have also found a positive correlation between Ki67 staining and uptake of 18 F-FDG in BC (31)(32)(33)(34), although this relationship is not well defined for lobular carcinoma, which has lower uptake of 18 F-FDG than does ductal carcinoma (31)(32)(33)35). Clinically, most data suggest there is no relationship between HER2 expression evaluated by immunohistochemical staining and tumor uptake of 18 F-FDG (32)(33)(34)36). Only Ueda et al found a positive correlation between expression of HER2 and tumor uptake of 18 F-FDG (35).…”

Section: Discussionmentioning

confidence: 99%

¹⁸F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice

McLarty¹,

Fasih²,

Scollard³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

Breast cancers (BCs) with high human epidermal growth factor receptor type 2 (HER2) expression are most likely to respond to trastuzumab; however, the mechanisms of action of trastuzumab are complex and there are no established biomarkers to accurately monitor treatment outcome in individual patients. Therefore, our aim was to determine, in human BC xenografts in athymic mice treated with trastuzumab, whether there were any changes in 18 F-FDG uptake that were associated with response to the drug and that could have utility in monitoring response in patients. Methods: Baseline tumor uptake of 18 F-FDG was measured in mice with MDA-MB-361 HER2-overexpressing xenografts and MDA-MB-231 xenografts with low HER2 expression by small-animal PET imaging on day 0. Mice were treated with phosphate-buffered saline (PBS) or trastuzumab (4 mg/kg), and small-animal PET was repeated 2 d after treatment. Maintenance doses of trastuzumab (2 mg/kg) or PBS were administered on days 7 and 14, and mice were imaged again on days 9 and 16. Tumor uptake was measured as percentage injected dose per gram (%ID/g) by volume-of-interest analysis on days 0 (baseline), 2, 9, and 16, followed by biodistribution studies on day 16. Tumor growth was measured, and a tumor growth index was calculated. Results: The treatment of mice with trastuzumab, compared with control mice treated with PBS, resulted in a significant decrease in tumor uptake of 18 F-FDG in HER2-overexpressing MDA-MB-361 xenografts after 16 d of treatment (2.6 6 0.8 %ID/g vs. 4.6 6 1.8 %ID/g, respectively; P , 0.03) but not after 2 or 9 d of treatment (P 5 0.28-0.32). In contrast, there was no significant change in the tumor uptake of MDA-MB-231 xenografts with low HER2 expression during the entire course of therapy (4.4 6 1.7 %ID/g vs. 3.6 6 1.1 %ID/g, respectively; P 5 0.31). Trastuzumab treatment, compared with PBS treatment of controls, resulted in significant growth inhibition of MDA-MB-361 xenografts as early as 10 d from the initiation of treatment (tumor growth index, 0.7 6 0.2 vs. 1.7 6 0.3, respectively; P , 0.0005), whereas no tumor growth inhibition was observed for MDA-MB-231 xenografts (5.3 6 2.7 and 5.2 6 3.0; P 5 0.95). Conclusion: Changes in the tumor uptake of 18 F-FDG after therapy accurately identified responding and nonresponding human BC xenografts in athymic mice treated with trastuzumab; however, diminished glucose utilization did not precede changes in tumor volume.

show abstract

“…However, 39% of patients had clinical stage T1. Given the limited spatial resolution, FDG PET can miss small lesions, and this is especially true for low-grade tumours and lobular carcinoma [10]. In a recent study, among 32 invasive tumours >2 cm, 31 (97%) were well visualized with FDG PET [8].…”

Section: Primary Tumour Assessmentmentioning

confidence: 99%

Should FDG PET/CT be used for the initial staging of breast cancer?

Groheux

Hindié

Rubello

et al. 2009

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer

Abstract: The SUV is a preoperative and non-invasive metabolic factor that relates to some prognostic factors in breast cancer.

Cited by 154 publications

References 12 publications

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

¹⁸F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice

Should FDG PET/CT be used for the initial staging of breast cancer?

Contact Info

Product

Resources

About

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer

Abstract: The SUV is a preoperative and non-invasive metabolic factor that relates to some prognostic factors in breast cancer.

Cited by 154 publications

References 12 publications

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer

18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice

Should FDG PET/CT be used for the initial staging of breast cancer?

Contact Info

Product

Resources

About

¹⁸F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice